Entero Healthcare Q4 FY26: Robust Revenue Growth Masks Margin Pressures and Profit Deceleration

While net sales surged 11.92% sequentially and 42.63% year-on-year to an all-time high of ₹1,909.93 crores in Q4 FY26, the pace of profit growth failed to keep pace, raising concerns about margin sustainability and cost management. For the full fiscal year FY26, consolidated net profit grew 9.03% year-on-year to ₹115.04 crores on revenues of ₹6,591.22 crores, marking a 29.37% increase over FY25.

The results underscore Entero Healthcare's ability to scale operations rapidly—net sales have grown at a five-year compound annual growth rate of 26.28%—but also highlight emerging challenges in converting revenue growth into proportionate bottom-line expansion. The company's profit after tax margin of 2.36% in Q4 FY26, whilst showing sequential improvement, remains modest for a retail-focused business model.

Financial Performance: Strong Top-Line Momentum Fails to Translate into Proportionate Profit Growth

Entero Healthcare's Q4 FY26 performance revealed a tale of two narratives. On the revenue front, the company delivered an impressive 11.92% quarter-on-quarter expansion to ₹1,909.93 crores, marking the seventh consecutive quarter of sequential growth and a robust 42.63% year-on-year surge. This top-line momentum reflects aggressive store expansion, enhanced product portfolio penetration, and favourable demand dynamics in India's organised pharmaceutical retail segment.

However, the translation of this revenue growth into bottom-line expansion proved challenging. Consolidated net profit of ₹28.01 crores in Q4 FY26 grew merely 1.38% quarter-on-quarter and actually declined 6.30% versus the previous four-quarter average of ₹29.84 crores. This profit deceleration occurred despite operating margins (excluding other income) improving to 4.50%—the highest level in the trailing eight quarters—up 53 basis points sequentially from 3.97% in Q3 FY26.

The margin improvement story was partially offset by rising interest costs, which climbed 23.55% quarter-on-quarter to ₹17.31 crores in Q4 FY26, reflecting the company's debt-funded expansion strategy. Depreciation charges also increased substantially by 50.92% to ₹14.79 crores, indicative of recent capital expenditure for new store rollouts and infrastructure upgrades.

Other income declined sharply to ₹4.01 crores in Q4 FY26 from ₹4.61 crores in the previous quarter and ₹7.29 crores in the year-ago period, representing a 13.02% sequential drop and a 45.00% year-on-year contraction. This reduction in non-operating income further pressured overall profitability despite operational improvements.

For the full fiscal year FY26, net sales reached ₹6,591.22 crores, representing 29.37% growth over FY25's ₹5,095.00 crores. Operating profit before depreciation, interest, and tax (PBDIT) excluding other income expanded to ₹266.00 crores with a margin of 4.04%, compared to ₹171.00 crores (3.36% margin) in FY25. However, consolidated net profit growth of 9.03% to ₹115.04 crores lagged revenue expansion significantly, underscoring the margin compression challenges facing the business.

Operational Challenges: Weak Return Ratios Signal Capital Efficiency Concerns

Beneath the headline revenue growth figures, Entero Healthcare's operational metrics reveal concerning trends in capital efficiency and profitability. The company's return on equity (ROE) of 6.26% and return on capital employed (ROCE) of 7.73% rank amongst the weakest in its peer group, signalling that the aggressive expansion strategy has yet to deliver commensurate returns on invested capital.

These modest return ratios reflect the capital-intensive nature of pharmaceutical retail expansion, where significant upfront investments in inventory, store infrastructure, and working capital precede profitability. Entero Healthcare's average sales-to-capital-employed ratio of 2.28x indicates moderate asset turnover efficiency, whilst the five-year EBIT compound annual growth rate of 56.53% demonstrates strong operational momentum that has yet to fully translate into superior return metrics.

The company's balance sheet reveals the financial strain of rapid expansion. Total shareholder funds stood at ₹1,724.14 crores as of March 2025, with negligible long-term debt of ₹0.00 crores (down from ₹45.54 crores in March 2024). However, current liabilities surged to ₹845.02 crores, driven primarily by trade payables of ₹397.30 crores (up 72.78% year-on-year) and other current liabilities of ₹146.22 crores.

Working capital management remains a critical challenge. The company reported negative cash flow from operations of ₹76.00 crores in FY25, driven by a ₹221.00 crores increase in working capital requirements. This operational cash burn was offset by ₹232.00 crores in cash flow from investing activities and ₹73.00 crores outflow in financing activities, resulting in a net cash inflow of ₹81.00 crores for the year.

The Debt Dynamics: Low Leverage Provides Financial Flexibility

One bright spot in Entero Healthcare's financial profile is its conservative leverage position. The company's debt-to-EBITDA ratio of 2.10x and net debt-to-equity ratio of 0.16x provide meaningful financial flexibility and cushion against adverse business cycles. With long-term debt virtually eliminated (₹0.00 crores as of March 2025), the company has successfully deleveraged its balance sheet whilst funding expansion through internal accruals and equity capital.

The average EBIT-to-interest coverage ratio of 2.61x, whilst modest, indicates adequate debt servicing capability. Interest expenses of ₹17.31 crores in Q4 FY26 represented 30.00% of profit before tax, down from 35.00% in the year-ago period, suggesting improving financial efficiency despite higher absolute interest costs driven by working capital financing.

Cash and cash equivalents stood at ₹229.00 crores as of March 2025, up from ₹147.00 crores in the previous year, providing a comfortable liquidity buffer. This cash position, combined with minimal long-term debt, positions Entero Healthcare favourably to navigate near-term challenges and fund organic growth initiatives without excessive dilution or financial strain.

Industry Leadership: How Entero Healthcare Compares to Peers

Within India's organised pharmaceutical retail sector, Entero Healthcare occupies a mid-tier position with a market capitalisation of ₹5,611.61 crores, ranking fourth amongst its immediate peer group. The company's valuation multiples and operational metrics reveal a mixed competitive positioning, with premium pricing on certain parameters offset by weaker profitability indicators.

At a price-to-earnings ratio of 47.88x based on trailing twelve-month earnings, Entero Healthcare trades at a premium to peers Shankara Buildpro (19.68x) and Khemani Distributors (20.06x), but below A B Lifestyle (60.00x) and Aditya Vision (58.62x). The company's price-to-book ratio of 3.24x positions it favourably against peers, with only Khemani Distributors (2.98x) trading at a lower multiple.

However, the company's return on equity of 6.26% significantly lags the peer group average. Aditya Vision leads with an impressive 29.42% ROE, followed by Khemani Distributors at 21.24% and A B Lifestyle at 11.08%. MedPlus Health Services, the closest comparable in terms of business model, posts a 6.80% ROE—marginally ahead of Entero Healthcare.

The peer comparison reveals that Entero Healthcare's premium valuation multiple of 47.88x earnings is not fully justified by its operational performance. Whilst the company demonstrates superior revenue growth rates compared to most peers, its weak return ratios and modest margins suggest limited pricing power and operational efficiency challenges. The stock's valuation appears predicated on future growth expectations rather than current profitability metrics.

Valuation Analysis: Premium Pricing Despite Operational Headwinds

Entero Healthcare's valuation metrics present a paradox—the stock trades at elevated multiples despite underwhelming profitability indicators. At ₹1,289.70 per share, the company commands a market capitalisation of ₹5,611.61 crores, implying a price-to-earnings ratio of 47.88x based on trailing twelve-month earnings and a price-to-book value of 3.24x against a book value per share of ₹395.31.

The enterprise value-to-EBITDA multiple of 26.25x and EV-to-EBIT of 31.31x further underscore the premium pricing. These multiples significantly exceed the broader retailing sector median and reflect investor optimism about the company's long-term growth trajectory in India's underpenetrated organised pharmaceutical retail market. However, the PEG ratio of 1.47x suggests that current valuations may be running ahead of near-term earnings growth potential.

Historical valuation analysis reveals that Entero Healthcare's valuation grade has oscillated between "Attractive" and "Very Attractive" over the past nine months, most recently classified as "Very Attractive" since September 12, 2025. This assessment reflects the stock's correction from its 52-week high of ₹1,509.90, with current levels representing a 14.58% discount to that peak.

The stock's 52-week trading range of ₹944.00 to ₹1,509.90 illustrates significant volatility, with current levels positioned 36.62% above the 52-week low. This volatility, reflected in a beta of 1.35, indicates higher risk compared to the broader market—a characteristic typical of small-cap growth stocks in emerging sectors.

Shareholding: Institutional Exodus Raises Red Flags

The shareholding pattern evolution over the past five quarters reveals a concerning trend of institutional investor exits, particularly amongst foreign institutional investors (FIIs). FII holdings plummeted from 19.92% in March 2025 to just 4.03% in March 2026—a dramatic 15.89 percentage point reduction representing significant institutional divestment.

The most pronounced FII selling occurred in the December 2025 quarter, when holdings dropped 9.53 percentage points from 14.67% to 5.14%, followed by further reduction to 4.03% in March 2026. This sustained institutional selling pressure suggests growing concerns amongst sophisticated investors about the company's near-term profit trajectory and valuation sustainability.

Mutual fund holdings showed volatility, declining from 10.25% in December 2025 to 9.52% in March 2026 after a sharp increase from 4.78% in September 2025. Other domestic institutional investors (DIIs) increased their stake modestly from 6.17% to 7.10% during the same period, partially offsetting the FII exodus but insufficient to reverse the negative sentiment signal.

Promoter holding remained stable at 52.42% throughout the five-quarter period, with no pledging of shares—a positive indicator of management confidence. The promoter group is led by Orbimed Asia III Mauritius Limited (38.01%), followed by individual promoters Prabhat Agrawal (9.26%) and Prem Sethi (5.15%).

The rise in non-institutional holdings from 18.02% in March 2025 to 26.93% in March 2026 suggests retail investor accumulation, potentially driven by momentum-based buying. However, the simultaneous institutional selling raises questions about information asymmetry and differing risk assessments between retail and institutional investor cohorts.

Stock Performance: Volatility Defines Recent Trading Pattern

Entero Healthcare's stock price trajectory over the past year reflects the broader challenges facing small-cap growth stocks in a volatile market environment. Over a one-year horizon, the stock has declined 12.15%, underperforming the Sensex's 7.25% decline by 4.90 percentage points, indicating relative weakness despite the broader market correction.

However, shorter-term performance metrics paint a more positive picture. Year-to-date returns of 25.73% significantly outpace the Sensex's 10.56% decline, generating alpha of 36.29 percentage points. Similarly, three-month returns of 20.24% and six-month returns of 22.82% demonstrate strong momentum in recent quarters, supported by the company's consistent revenue growth and improving operating margins.

The stock's technical profile shows a bullish trend that commenced on May 19, 2026, at ₹1,242.55, following a period of mildly bullish sentiment. Current levels of ₹1,289.70 position the stock above its 50-day moving average of ₹1,198.45, 100-day moving average of ₹1,155.47, and 200-day moving average of ₹1,138.44, suggesting positive momentum across multiple timeframes.

However, the stock trades below its 5-day moving average of ₹1,301.76 and 20-day moving average of ₹1,233.04, indicating near-term consolidation following the recent rally. The immediate resistance zone lies at ₹1,362.80 (day's high), with major resistance at the 52-week high of ₹1,509.90. Support is established at the 52-week low of ₹944.00, representing a 26.79% downside buffer from current levels.

Risk-adjusted return analysis reveals a negative Sharpe ratio over the one-year period, with absolute returns of -12.15% and volatility of 37.11%. This high-risk, negative-return profile classifies Entero Healthcare as a "HIGH RISK MEDIUM RETURN" investment, with beta of 1.35 indicating 35.00% higher volatility than the broader market.

Investment Thesis: Quality Concerns Overshadow Growth Momentum

Entero Healthcare's investment thesis rests on three pillars: valuation, quality, and financial/technical trends. The company's proprietary Mojo Score of 68 out of 100 places it in the "HOLD" category, reflecting a balanced but cautious assessment across these parameters.

From a valuation perspective, the stock is classified as "Very Attractive" following its correction from 52-week highs. However, this attractiveness is relative to recent peak valuations rather than absolute metrics—the 47.88x P/E ratio remains elevated for a company with 6.26% ROE and modest profit margins.

The quality assessment reveals significant weaknesses. Entero Healthcare is rated "AVERAGE" on quality parameters, constrained by weak return ratios (ROE of 6.26%, ROCE of 7.73%), modest interest coverage of 2.61x, and negative operating cash flows of ₹76.00 crores in FY25. Whilst the company demonstrates healthy long-term growth (26.28% sales CAGR, 56.53% EBIT CAGR), the inability to convert this growth into superior returns on capital raises fundamental concerns.

Near-term drivers appear favourable, with quarterly financial trends classified as "Positive" and technical indicators showing "Bullish" momentum. The company achieved record quarterly revenues of ₹1,909.93 crores and highest operating margins of 4.50% in Q4 FY26, whilst six-month PAT growth of 22.24% demonstrates improving profitability trends.

However, the overall assessment remains mixed. Positive near-term trends and attractive relative valuation are offset by average quality metrics and concerns about sustainable margin expansion. The stock's HOLD rating reflects this balanced outlook—appropriate for existing holders but not compelling enough to warrant fresh accumulation at current valuations.

Key Strengths & Risk Factors

Outlook: What to Watch